-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $36

Benzinga·08/06/2026 10:08:27
Listen to the news
Stifel analyst Stephen Willey initiates coverage on Lyell Immunopharma (NASDAQ:LYEL) with a Buy rating and announces Price Target of $36.